# A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

> **NCT01194375** · PHASE2 · COMPLETED · sponsor: **Dow Pharmaceutical Sciences** · enrollment: 180 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Low Strength IDP-107
- **DRUG:** High Strength IDP-107
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01194375
- **Lead sponsor:** Dow Pharmaceutical Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2012-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01194375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01194375, "A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01194375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*